Fushilai released its 2026 interim report, with net profit attributable to the parent company at negative 14.6171 million yuan, swinging from profit to loss. The company's total operating revenue was 185 million yuan, down 17.17% year-on-year; net cash flow from operating activities was negative 26.7376 million yuan, down 154.91% year-on-year. The company's latest asset-liability ratio was 10.17%, gross margin was 14.00%, ROE was negative 0.80%, and diluted earnings per share was negative 0.17 yuan.
Suzhou Fushilai Pharmaceutical Co. Ltd.Net loss of 14.6171 million yuan, revenue down 17.17%, and negative operating cash flow.